What are analysts Suggestions on EP Energy Corporation(NYSE:EPE): Zynerba Pharmaceuticals, Inc.(NASDAQ:ZYNE)

0
10

EP Energy Corporation (EPE) will report its next earnings on Mar 20 AMC. The company reported the earnings of $-0.04/Share in the last quarter where the estimated EPS by analysts was $-0.01/share. The difference between the expected and actual EPS was $-0.03/share, which represents an Earnings surprise of -300%.

Many analysts are providing their Estimated Earnings analysis for EP Energy Corporation and for the current quarter 11 analysts have projected that the stock could give an Average Earnings estimate of $-0.13/share. These analysts have also projected a Low Estimate of $-0.18/share and a High Estimate of $-0.07/share.

In case of Revenue Estimates, 9 analysts have provided their consensus Average Revenue Estimates for EP Energy Corporation as 290.81 Million. According to these analysts, the Low Revenue Estimate for EP Energy Corporation is 277.6 Million and the High Revenue Estimate is 309 Million. The company had Year Ago Sales of 224 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for EPE to be -85.7%. They are projecting Next Quarter growth of -171.43%. For the next 5 years, EP Energy Corporation is expecting Growth of -174.9% per annum, whereas in the past 5 years the growth was 38.46% per annum.

Some buy side analysts are also providing their Analysis on EP Energy Corporation, where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for EP Energy Corporation might touch $1.5 high while the Average Price Target and Low price Target is $0.98 and $0.5 respectively.

EP Energy Corporation closed its last trading session at $0.62 with the loss of -0.02%. The Market Capitalization of the company stands at 156.18 Million. The Company has 52-week high of $3.50 and 52-week low of $0.52. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -4.2% where SMA50 and SMA200 are -15.71% and -62.97% respectively. The Company Touched its 52-Week High on 05/21/18 and 52-Week Low on 02/28/19.

The Relative Volume of the company is 1.49 and Average Volume (3 months) is 768.1 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -3.1%. The Return on Equity (ROE) value stands at -42.3%. While it’s Return on Investment (ROI) value is 3%.

While looking at the Stock’s Performance, EP Energy Corporation currently shows a Weekly Performance of 1.74%, where Monthly Performance is -8.46%, Quarterly performance is -37.37%, 6 Months performance is -64.77% and yearly performance percentage is -64.77%. Year to Date performance value (YTD perf) value is -11.43%. The Stock currently has a Weekly Volatility of 8.04% and Monthly Volatility of 9.96%.

Zynerba Pharmaceuticals, Inc. (ZYNE) will report its next earnings on Mar 18 BMO. The company reported the earnings of $-0.44/Share in the last quarter where the estimated EPS by analysts was $-0.65/share. The difference between the expected and actual EPS was $0.21/share, which represents an Earnings surprise of 32.3%.

Many analysts are providing their Estimated Earnings analysis for Zynerba Pharmaceuticals, Inc. and for the current quarter 5 analysts have projected that the stock could give an Average Earnings estimate of $-0.55/share. These analysts have also projected a Low Estimate of $-0.77/share and a High Estimate of $-0.46/share.

These analysts also forecasted Growth Estimates for the Current Quarter for ZYNE to be 15.4%. They are projecting Next Quarter growth of 12.36%. For the next 5 years, Zynerba Pharmaceuticals, Inc. is expecting Growth of 1.01% per annum, whereas in the past 5 years the growth was -1.53% per annum.

Some buy side analysts are also providing their Analysis on Zynerba Pharmaceuticals, Inc., where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Zynerba Pharmaceuticals, Inc. might touch $26 high while the Average Price Target and Low price Target is $14.63 and $5.5 respectively.

Zynerba Pharmaceuticals, Inc. closed its last trading session at $5.11 with the loss of -0.2%. The Market Capitalization of the company stands at 87.46 Million. The Company has 52-week high of $12.50 and 52-week low of $2.75. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 0.45% where SMA50 and SMA200 are 10.2% and -23.74% respectively. The Company Touched its 52-Week High on 06/22/18 and 52-Week Low on 12/31/18.

The Relative Volume of the company is 0.43 and Average Volume (3 months) is 912.77 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -63.3%. The Return on Equity (ROE) value stands at -74.8%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, Zynerba Pharmaceuticals, Inc. currently shows a Weekly Performance of 7.82%, where Monthly Performance is -1.73%, Quarterly performance is 10.39%, 6 Months performance is -25.87% and yearly performance percentage is -51.57%. Year to Date performance value (YTD perf) value is 71.72%. The Stock currently has a Weekly Volatility of 7.29% and Monthly Volatility of 6.72%.

SHARE